Mesa Labs Announces Agreement to Acquire GKE-GmbH companies

October 16, 2023

Gary Owens, President and CEO

John Sakys, CFO

John Sullivan, Chairman and Investor Relations

Safe Harbor Statement

This presentation release contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, express or implied statements or guidance regarding the expected effect of the acquisition of GKE-GmbH, SAL GmbH and Beijing GKE Science & Technology

CO. LTD (collectively "GKE") on Mesa's future financial performance, including revenues and income growth, the accretive nature and the

timing of the accretive nature of the acquisition, expected synergies following the acquisition of GKE, customer adoption of GKE's products, the expected expansion of Mesa's product lines, the timing of the closing of the GKE China acquisition and other statements

identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking

statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the risk that the proposed acquisition may not be completed in a timely manner, or at all; the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition; our ability to integrate GKE's business and personnel and to achieve expected synergies; our ability to maintain or expand GKE's historical sales; our ability to accurately forecast the acquisition, related restructuring costs and allocation of the purchase price, goodwill and other acquired intangibles and other asset adjustments; the risk of any litigation relating to the transaction; and other risks detailed in Mesa's most recent Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Mesa periodically files with the Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. These forward-looking statements reflect management's current views and are based only on information currently available to us. Mesa does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of new information or otherwise, that occur after the date hereof except as required by law.

In this presentation, we refer to non-GAAP financial measure adjusted operating income ("AOI") which is defined to exclude the non-cash impact of amortization of intangible

assets, stock-based compensation expense, and impairment loss on goodwill and long-lived assets. We are unable to provide a reconciliation of forward-looking AOI because components of the calculation are inherently unpredictable and currently unknown.

2

Strategic Rationale

Complementary Products

Complementary Customer Access

The Mesa Way

Strength in chemical indicators complementing Mesa's strength in biologic indicators which are used in the same sterility validation workflows

Deep healthcare focused commercial capability and geographic coverage complement Mesa's life science expertise

Opportunity to leverage The Mesa Way to accelerate sustainable growth in a highly attractive business

Accretive to Mesa on multiple levels

3

GKE Businesses Snapshot

100.0%

80.0%

60.0%

40.0%

20.0%

0.0%

North America 4%

OEM

Mesa:

Life Science 7%

~70%

OEM & Ancillary

RoW

12%

18%

14%

Direct

Testing 2%

APAC (ex China)

17%

Cleaning 7%

15%

Mesa:

Biological Indicators

~80%

12%

China

22%

Healthcare

Distribution

93%

71%

Chemical Indicators

Europe

61%

44%

Geography

Channel

Product

Vertical

Revenues* €19- €20M

MSD Long Term

Core Revenues

Growth*

GP%^ low 70s

AOI%*^ 37% - 40%

Note: *Represents Mesa's first full year of ownership and excludes COVID related revenues ^Exclusive of the impact of purchase accounting and integration expenses

Global presence, local intimacy, with complimentary product and vertical strengths

4

GKE Healthcare Applications

Chemical Indicators

Medical instrument sterility assurance

Medical Procedure

Sterile Storage

Initial Wash

Chemical Indicators

Proof of sterilization and data tracking

Broad indicator portfolio

focused on healthcare sterilization workflows

Cleaning Indicators

Routine monitoring of validated instrument

wash cycles

Sterilization Cycle

Sterilization Prep

Biological & Chemical Indicators

Chemical Indicators

Validate sterility

Indicators added to each instrument package

Differentiated, proven, flexible platform of sterilization indicators for healthcare

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Mesa Laboratories Inc. published this content on 16 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 October 2023 16:38:25 UTC.